ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ: ADMA ) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.